RPRX

Healthcare Biotechnology

Royalty Pharma plc

$57.16

-0.08 -0.14% today

Price History

Not enough data

Key Stats

Market Cap

25.45B

Avg Volume

2.91M

P/E (TTM)

30.73

EPS

$1.86

52W High

$64.38

52W Low

$35.23

Div. Yield

1.6%

Analyst Ratings

Buy

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

9.97

P/B Ratio

3.68

P/S Ratio

13.02

EV/EBITDA

23.46

EV/Revenue

14.40

PEG Ratio

1.33

Margins

Gross Margin 95.8%

Operating Margin 19.7%

Net Margin 32.0%

EBITDA Margin 61.4%

Growth & Returns

Revenue Growth (YoY)

16.5%

Earnings Growth (YoY)

(46.3%)

Earnings Growth (QoQ)

(44.4%)

Return on Equity

14.0%

Return on Assets

5.1%

Liquidity & Leverage

Current Ratio

2.80

Quick Ratio

2.79

Debt / Equity

0.92

Total Cash

836.99M

Total Debt

8.96B

About

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.